Gentamicina Hexal

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gentamicina Hexal

Property Description
Active Ingredient Gentamicin Sulfate
Primary Form Sterile aqueous solution for injection
Pharmacological Class Aminoglycoside antibiotic
General Purpose To combat serious bacterial infections
Origin Semi-synthetic (derived from Micromonospora species)

Gentamicina Hexal is a potent, prescription-only systemic anti-infective defined by its sole active ingredient, Gentamicin Sulfate. Manufactured by Hexal, this product belongs to the Aminoglycoside antibiotic pharmacological class. The product is derived from a semi-synthetic process, tracing its origin to natural compounds produced by Micromonospora species.

What Type of Medicine is Gentamicina Hexal?

Gentamicina Hexal is classified as a potent, bactericidal, Aminoglycoside antibiotic used exclusively for combating severe bacterial infections, particularly in hospitalized patients or those in critical care settings. This classification indicates a powerful mechanism distinct from bacteriostatic agents. The drug's identity as a single-component product underscores that its pharmacological effects are derived entirely from the actions of Gentamicin (Gentamicin Sulfate), which requires parenteral administration to achieve systemic efficacy due to poor oral absorption.

Composition and Pharmaceutical Form

The medicine's active core is Gentamicin Sulfate, the chemical entity responsible for its anti-pathogen action, contained within a suitable sterile base. For systemic treatment, the primary pharmaceutical form of Gentamicina Hexal is a sterile aqueous solution for injection, formulated for administration via the intravenous (IV) or intramuscular (IM) route. While this injectable form is vital for systemic use, Gentamicin is also incorporated into topical ophthalmic and dermatological preparations where the medicine acts locally on the surface without significant absorption into the bloodstream.

General Purpose and Action Principle

The general purpose of this medicine is to rapidly achieve pathogen clearance for severe, systemic bacterial infections where efficient and definitive elimination of the organism is required, such as managing a hospital-acquired bloodstream infection. Gentamicin achieves this critical function by operating as a powerful bactericidal agent: it works by binding to the bacterial machinery—specifically the 30S ribosomal subunit—to inhibit protein synthesis, leading directly and quickly to the death of the targeted pathogens.

What side effects are possible with Gentamicina Hexal?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety considerations for Gentamicina Hexal, based strictly on government regulatory documents.


Serious Adverse Reactions and Organ Toxicity

Serious adverse reactions documented in regulatory sources include anaphylactic shock, acute renal failure, and neuromuscular blockade, which may lead to respiratory paralysis. The primary safety concerns revolve around Target Organ Toxicity:

  • Nephrotoxicity (Kidney Damage): This is the most common adverse reaction. It is typically reversible and related to the duration and total exposure to the medicine. Regular monitoring of renal function is required.
  • Ototoxicity (Ear Damage): This is a rare, but potentially irreversible, complication affecting both hearing and balance (vestibular function). The risk increases with higher drug levels (trough concentrations) and prolonged treatment.

Adverse Reaction Classification

Frequency Examples of Adverse Reactions (by System-Organ Class)
Common Nephrotoxicity (Renal and Urinary Disorders)
Uncommon Hypersensitivity reactions (e.g., rash, pruritus) (Immune System Disorders)
Rare Ototoxicity, acute renal failure, neuromuscular blockade, blood dyscrasias (e.g., thrombocytopenia), electrolyte disturbances (e.g., hypomagnesemia)
Not Known Anaphylactic shock

Safety Considerations

Regulatory documents specify increased susceptibility to toxicity in certain populations. Elderly patients, neonates/premature infants, and individuals with pre-existing renal impairment require particular caution due to a higher risk of ototoxicity and nephrotoxicity. Caution is also necessary in patients with conditions like myasthenia gravis or Parkinson's disease due to the potential for neuromuscular blockade. The risk of toxicity is significantly increased by the concurrent or sequential use of other oto- or nephrotoxic medicinal products.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Gentamicin Sulfate, which typically results from excessive serum concentrations, is officially documented by regulators as potentially leading to severe, organ-specific toxicity. The primary manifestations include damage to the eighth cranial nerve (Ototoxicity), which may cause persistent issues with hearing (tinnitus, hearing loss) and balance (vertigo, dizziness). The drug is also associated with damage to the kidneys (Nephrotoxicity), indicated by changes in the frequency or amount of urine.

Patients with impaired renal function, advanced age, or dehydration face an increased risk of these toxic reactions. The most severe, life-threatening outcomes documented in regulatory labeling include neuromuscular blockade, which may progress to respiratory paralysis, as well as acute renal failure and seizures.

Regulatory guidance emphasizes that immediate medical attention is required for a suspected overdose or the manifestation of any severe symptoms. The drug must be discontinued upon evidence of ototoxicity or nephrotoxicity. While no specific antidote is known for general overdose, management is symptomatic and supportive. Procedural steps described include hemodialysis to aid drug removal and the intravenous administration of calcium to address neuromuscular blockade. Close monitoring of drug serum levels and renal function is mandated during assessment.

Therapeutic Uses of Gentamicina Hexal

What Gentamicina Hexal Treats: Main Uses and Benefits

Gentamicina Hexal is a prescription-only antibiotic that is commonly used for managing severe bacterial infections where supporting the management of bacterial pathogens is appropriate. Its use is confined to situations requiring decisive medical intervention due to high acuity, often in hospitalized patients. This medication is commonly used for serious infections of the blood (Septicemia), central nervous system (Meningitis), lungs, skin, bone, and complicated urinary tract infections.


Key Therapeutic Focus

The medication is relevant in clinical settings that involve acute or unstable symptom patterns, such as those seen in conditions involving acute physiological stress. This includes managing conditions presenting with systemic or localized discomfort and addressing symptoms that become more disruptive during flare-ups, like debilitating high fevers and profound illness. Its application is relevant for easing challenging symptoms during these difficult episodes.

“This medication is used for managing infections where bacteria have invaded the bloodstream or critical organs.”

The use is also relevant for managing deep-seated, conditions where functional stability becomes affected, that involve organ-specific functional stress, including infections of the bone (Osteomyelitis) and widespread bacterial colonization of soft tissues. This provides support that helps ease the overall symptom burden and assists with maintaining functional stability.


Quick Fact: Support for Systemic Imbalance Gentamicina Hexal is commonly used to help manage symptoms related to systemic imbalance and heightened physiological activity that characterize conditions associated with acute or disruptive episodes.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Gentamicina Hexal?

The population eligibility for Gentamicina Hexal (Gentamicin Sulfate) is strictly defined by government regulatory documents, outlining populations that are strictly prohibited from use and those requiring conditional use.


Absolute Non-Eligibility (Contraindications)

This medicine must not be used by individuals with:

  • A known hypersensitivity or allergy to Gentamicin or any other Aminoglycoside antibiotic (due to cross-sensitivity).
  • Certain neuromuscular disorders, such as Myasthenia Gravis.

Conditional Eligibility and Restrictions

Use is established across all age groups (neonates, children, adults, older adults) but is subject to mandatory regulatory constraints:

  • Renal Impairment: Patients with reduced kidney function are eligible but require dose reduction and intensive monitoring of kidney function, as explicitly stated in the prescribing information.
  • Auditory Risk: Patients with pre-existing hearing or balance disorders must be treated with caution due to the risk of irreversible ototoxicity.
  • Pregnancy and Lactation: Use is not recommended during pregnancy due to the regulatory-documented risk of fetal harm. Caution is also advised during lactation.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Gentamicina Hexal (Gentamicin Sulfate) is defined by official regulatory requirements concerning additive toxicity and physical incompatibilities with co-administered substances. All listed restrictions are based strictly on government prescribing information.

Interactions Requiring Avoidance or Caution

The systemic use of Gentamicin requires the avoidance of concurrent or sequential use with medicines that carry a risk of toxicity to the kidneys (nephrotoxicity) or the inner ear (ototoxicity). This is due to the potential for additive toxicity when combined.

Substance Category Examples Restriction Basis
Nephrotoxic/Neurotoxic Drugs Vancomycin, Cisplatin, Amphotericin B, other Aminoglycosides Avoid due to Additive Toxicity
Potent Diuretics Furosemide, Ethacrynic Acid Avoid due to potential to Enhance Toxicity
Neuromuscular Blocking Agents Curare-type muscle relaxants Use with Caution (risk of paralysis)

Restrictions Due to Physical Incompatibility

Gentamicin is physico-chemically incompatible with several products and must not be mixed in the same infusion solution, including certain beta-lactam antibiotics (like penicillins), Heparin sodium, and Furosemide. Administration must occur at separate sites or with adequate flushing to prevent inactivation. Cautions regarding increased risk of toxicity are also noted for populations with advanced age or dehydration.

Mechanism of Action

The action of Gentamicin Sulfate is a targeted mechanism that causes the rapid demise of susceptible bacterial cells through the disruption of their essential protein-building machinery and subsequent structural failure.

Irreversible Inhibition of the Bacterial Protein Factory

The drug’s initial action involves a specific, irreversible binding to the bacterial 30S ribosomal subunit, particularly at the 16S ribosomal RNA within the A-site. This engagement immediately disrupts the cell’s core biological function: protein synthesis (translation). This specific molecular targeting initiates the functional shutdown of the pathogen's essential cellular processes.

Mechanism of Lethal Translational Errors and Cellular Collapse

Gentamicin's binding actively forces the ribosome to misread the genetic code (mRNA), leading to the synthesis of non-functional and defective proteins. These faulty proteins are integrated into the bacterial cell envelope, causing critical loss of membrane integrity and structural failure. This cascade of molecular errors culminates in the swift and irreversible bactericidal effect, resulting in the death of the targeted microbial cells.

Constraints on Drug Access and Resistance Mechanisms

The mechanism's efficacy is biologically dependent on the bacterial cell's energy state, as initial uptake requires an oxygen-dependent transport system across the cell membrane. Consequently, the drug’s action is constrained in anaerobic or acidic environments. Furthermore, the mechanism can be overridden by bacterial aminoglycoside-modifying enzymes (AMEs), which chemically inactivate the drug before it can bind to its 30S target.

Dosage and Administration Information

How to Use Gentamicina Hexal

Gentamicin is an antibiotic administered under strict medical supervision and its usage is defined by precise regulatory protocols to ensure appropriate systemic exposure. The administration method is primarily parenteral, meaning it is given by injection rather than orally.


Official Administration Protocol

Usage Constraint Official Requirement
Route of Administration Administered via Intramuscular (IM) injection or as a slow Intravenous (IV) infusion.
Preparation Requirement The solution must be diluted in 50 to 200 mL of sterile isotonic saline or 5% dextrose solution prior to IV infusion.
Infusion Duration The diluted dose must be infused over a period of 30 minutes to two hours to avoid rapid, excessive serum levels.
Typical Duration Treatment is generally limited to a short course, typically seven to ten days.

Official Dosing and Adjustment Rules

The dosage schedule is weight-based, requiring the calculation of the correct quantity using the patient’s pretreatment body weight or estimated lean body mass. The standard adult daily dose for serious infections is often 3 mg/kg of body weight, which may be divided into doses administered every eight hours (q8h) or given as a single daily dose (q24h), depending on the specific protocol.

Specific adjustments are mandated for certain patient populations. For patients with impaired renal function, the dosage schedule must be formally reduced (by either lowering the dose or prolonging the interval between doses) based on assessment of kidney function. Pediatric and neonatal patients also require distinct weight-based regimens tailored to their age and metabolic rate. Furthermore, the protocol requires Therapeutic Drug Monitoring (TDM)—laboratory measurement of drug levels in the bloodstream—to guide all necessary dose and interval adjustments.

Recent Clinical Evidence

Research evidence / Overview of studies for Gentamicina Hexal

Evidence for Use in Severe Systemic Bacterial Infections

The research base for Gentamicin (the active component in Gentamicina Hexal) is documented in many sources, as it has a long regulatory history. This body of evidence includes a high number of Randomized Controlled Trials (RCTs) and Systematic Reviews that have explored its role in severe infections, such as those of the bloodstream (Septicemia), the central nervous system (Meningitis), and complicated Urinary Tract Infections (UTIs). Studies have primarily focused on patients requiring hospitalization due to the seriousness of their condition.

Researchers examined outcomes related to microbiological pathogen clearance (meaning the measurement of bacterial reduction or removal) and monitored overall clinical outcomes as defined by specific study protocols. A significant portion of the research has been dedicated to Pharmacokinetic/Pharmacodynamic (PK/PD) studies. These studies examined how the drug is handled in the body, specifically measuring therapeutic drug concentrations in the bloodstream.

Evidence for Localized Application in Ménière's Disease

Research has explored a distinct, localized application of the drug (known as intratympanic administration) for symptoms associated with Ménière's disease, a condition characterized by fluctuating or episodic manifestations of vertigo. The evidence base here is much more focused, primarily consisting of a small number of RCTs and subsequent Systematic Reviews.

Research focusing on conditions involving periods of heightened symptoms has evaluated outcomes related to physical discomfort and changes in vestibular function. Findings were mixed across the few available trials included in the reviews. The sample sizes were modest, and follow-up durations were limited, contributing to the finding that certainty remains low.

What Is Still Uncertain About Gentamicina Hexal Research

The complete body of research highlights several key areas where more understanding is needed. Evidence quality varies across studies, with some older trials lacking the methodological rigor of modern RCTs. For the severe systemic indications, comparative evidence is lacking for certain new treatment protocols, and the use of the drug is often inferred from studies involving combination therapy. Furthermore, long-term effects are not fully established across all populations, and specific subgroup findings are uncertain.

Key Studies & References

  1. Clinical pharmacology of gentamicin in neonates: regimen, toxicology and pharmacokinetics
  2. Prophylaxis with systemic antibiotics versus gentamicin bone cement in total hip arthroplasty. A five-year survey of 1688 hips

Frequently Asked Questions (FAQ)

Common questions about Gentamicina Hexal (FAQ)

Q: How quickly should I notice an improvement after starting Gentamicina Hexal?

A: Gentamicin is classified as a bactericidal antibiotic, meaning its mechanism of action is designed to rapidly disrupt the bacteria’s ability to build proteins, leading to cell death. While the drug works quickly at the cellular level, official prescribing information does not provide a specific timeline for when a patient should notice subjective clinical improvement.

Q: Is it common to feel a slight burning sensation when first applying the ointment?

A: When using the topical forms of gentamicin, local reactions such as irritation, redness, itching, or swelling are listed as less common side effects. A slight burning sensation may be part of this general local irritation, but it is not commonly reported in the official safety information.

Q: Can children use Gentamicina Hexal for skin conditions?

A: The injectable form has established, weight-based dosage regimens for use in pediatric patients. For the topical form, one regulatory-referenced source indicates that the medicine has been safely used in children over one year of age and does not typically cause different side effects than those observed in adults.

Q: What happens if I accidentally swallow a tiny bit of the Gentamicina Hexal cream?

A: Gentamicin is known to be poorly absorbed through the gastrointestinal tract, which is the reason why the medicine must be given by injection to treat severe systemic infections. The official labeling for the topical cream does not specifically address the safety of minor, accidental oral ingestion.

Q: How does Gentamicina Hexal interact with a potent diuretic like Furosemide?

A: Regulatory drug interaction information restricts the concurrent or sequential use of Gentamicin with potent diuretics, such as Furosemide or Ethacrynic Acid. This is because these combinations have the potential to increase the risk of serious side effects, specifically ototoxicity (damage to the inner ear) and nephrotoxicity (kidney damage).

Q: How can I tell the difference between a side effect and an allergic reaction to Gentamicina Hexal?

A: Hypersensitivity (allergic) reactions like rash, itching, or swelling are listed as uncommon side effects. Serious allergic reactions such as anaphylactic shock are possible. A suspected serious allergic reaction requires prompt attention from a healthcare professional.

Q: Can Gentamicina Hexal be used safely during pregnancy?

A: The use of Gentamicin during pregnancy is generally not recommended according to official regulatory documents. This is because aminoglycosides are known to cross the placenta and carry a regulatory-documented risk of causing fetal harm, including the risk of irreversible congenital deafness, as observed with similar drugs in this class.

Q: How long does Gentamicina Hexal stay in your system after stopping treatment?

A: For adults with normal kidney function, the half-life of Gentamicin in the serum is typically short, around three to three and a half hours. However, the drug is known to accumulate in body tissues, particularly the kidneys, and total clearance from the body can take longer, particularly in individuals with reduced kidney function.

Q: What should I do if the application area becomes redder or itchier after using Gentamicina Hexal?

A: Local reactions like itching, redness, swelling, or general irritation in the area of application are known, but less common side effects. If symptoms become worse or persist over time, it is important to bring this to the attention of a healthcare professional for assessment.

Q: Can Gentamicina Hexal cause stinging when applied to an open wound?

A: Official safety information for the ophthalmic (eye) preparations of Gentamicin mentions eye burning and eye stinging as possible reactions. For general topical use, the label typically reports local irritation, redness, and itching.

Q: What are the signs of systemic absorption when using topical Gentamicina Hexal?

A: Systemic absorption, meaning the medicine enters the bloodstream, is rare but can occur if the topical medicine is applied to large or broken areas of skin. Signs of potential systemic toxicity (neurotoxicity) may include sensory changes such as numbness, tingling, or muscle twitching, as well as signs of ototoxicity (dizziness, ringing in the ears).

Q: Does using Gentamicina Hexal increase my sensitivity to other drugs?

A: Gentamicin does not cause a generalized increase in a person’s sensitivity to other drugs. The primary concern is the potential for additive toxicity when combined with other specific medicines, which is the regulatory basis for the restrictions on concurrent use with nephrotoxic or ototoxic agents.

Q: How soon can I stop using Gentamicina Hexal once my symptoms disappear?

A: Official guidance emphasizes the importance of completing the full course of therapy as prescribed, even if symptoms have cleared. Stopping treatment early may risk incomplete elimination of the infection or contribute to antibiotic resistance.

Q: Can Gentamicina Hexal affect the results of any laboratory tests?

A: Yes, regulatory information requires laboratory monitoring of the drug's serum levels (TDM) and of renal function. Furthermore, the drug is known to potentially cause electrolyte disturbances, such as changes in magnesium or potassium levels, which could affect the results of other standard laboratory panels.

Q: What is the evidence supporting the use of Gentamicina Hexal for bacterial skin infections?

A: The topical preparation of Gentamicin is officially indicated for the treatment of minor skin infections caused by susceptible bacteria. While the primary body of regulatory research overviews focuses on the systemic use for severe hospitalized infections, the product label confirms its established use for these bacterial skin conditions.

Q: Does the application of heat or cold affect how well Gentamicina Hexal works?

A: Official storage instructions for the Gentamicin injection strictly warn against exposure to extreme temperatures, requiring the medicine to be stored at a controlled room temperature to maintain its quality. These precautions relate to the stability of the medicine itself, but there are no specific regulatory statements on how external heat or cold should be applied during the course of a topical treatment.

Q: Are there any foods or drinks that interact with the effectiveness of Gentamicina Hexal?

A: Official drug interaction lists are focused on interactions with other medicines. However, some official references suggest that general discussions with a healthcare professional regarding the use of medicine alongside food, alcohol, or tobacco can help clarify potential effects on drug absorption or action.

Q: Is it possible to be allergic to the inactive ingredients in Gentamicina Hexal?

A: The medicine is strictly contraindicated for anyone with a known hypersensitivity to Gentamicin or other Aminoglycosides. Some official labels also state that the product is contraindicated in individuals with known or suspected allergy to any of the ingredients in the preparation, which would include inactive components.

Q: Can I use Gentamicina Hexal if I have Myasthenia Gravis?

A: No. Official regulatory documents list Myasthenia Gravis as an absolute contraindication for Gentamicin. This is because aminoglycosides have the potential to aggravate muscle weakness due to their effects on the neuromuscular system, which can, in rare cases, lead to breathing difficulties.

How should Gentamicina Hexal be stored and disposed of?

The storage and disposal of Gentamicin Sulfate solution must strictly adhere to regulatory requirements to ensure product quality and safety.

Mandatory Storage Conditions

Category Requirement as Documented in Official Labeling
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F). Do not refrigerate or freeze.
Protection Store in the original package to protect it from light. Keep the container tightly closed.
Child Safety The medicine must be kept out of the reach of children.

Stability and Disposal

The chemical and physical stability of the solution after dilution (e.g., with 0.9% sodium chloride) is demonstrated for 24 hours at 25 C. However, the labeling microbiologically recommends immediate use of the opened product. Any unused medicinal product or waste material must be disposed of in accordance with local requirements. Disposal should utilize a drug take-back program when available, and the product must not be flushed down the sink or toilet unless explicitly instructed by the labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gentamicina Hexal found in:

A-Z Index: